Cardiolynx Receives Patent on Improved Angina Pectoris Drug
Cardiolynx Ltd., specializing in the development of improved cardio-metabolic therapies, announced that the European Patent Office (EPO) has granted a patent covering a new chemical entity, CLC-1280, developed using Cardiolynx' nitric oxide technology. CLC-1280 is based on an established late lifecycle product and is being developed for treating hypertensive patients with angina pectoris.
The Cardiolynx technology employs specific vasodilating chemical linkers as grafts onto or in combination with established cardiovascular drugs resulting in a dual mode of action: the original mode of action of the established product plus the synergistic vasodilative mode.
Dr. Dirk Sartor, CEO of Cardiolynx, commented: "CLC-1280 is active in preclinical models of vasodilatation and has the potential to reduce blood pressure and prevent or reduce angina pectoris thus improving the standard care of this chronic and debilitating condition. The new patent strengthens Cardiolynx's intellectual property portfolio which includes four patent families with pending applications worldwide."
Original publication
Knorr M et al.: "Characterization of new organic nitrate hybrid drugs covalently bound to valsartan and cilostazol."; Pharmacology 2012; 90: 193-204.
Original publication
Knorr M et al.: "Characterization of new organic nitrate hybrid drugs covalently bound to valsartan and cilostazol."; Pharmacology 2012; 90: 193-204.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

New Strategy Against Osteoporosis - An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health

Fraunhofer-Institut für Zuverlässigkeit und Mikrointegration (IZM) - Berlin, Germany

Merck acquires Swiss biotech start-up - Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

Evonik Venture Capital invests in Laxxon - 3D printed tablets with better drug delivery

Ori Biotech raises over $100 million in Series B funding - Innovative cell and gene therapy manufacturing platform
Enzymes open up new avenues in the chemical industry - BASF steps up White Biotechnology operations
Solvay finalizes agreement to buy Fournier Pharma
Benitec Initiates Patent Infringement Lawsuit
PerkinElmer And BioImage Announce Collaboration For Cell-Based Screening Applications
